Investigational drug · Phase 3
ponsegromab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "ponsegromab"
First trial start
2025
Oct 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ponsegromab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cachexia
- Metastatic Pancreatic Ductal Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ponsegromab" as an intervention, largest first.
- A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatiguePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06989437 · 982 participants (planned) · Start Oct 3, 2025 · Primary completion Jan 23, 2028
Drug: ponsegromab; placebo · For: Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 230 sites in all
- A Study of Ponsegromab in People With Heart FailurePivotal-lookingTerminated
PfizerPfizer (PFE)
NCT05492500 · 455 participants · Start Sep 26, 2022 · Primary completion Mar 5, 2025
Drug: Main cohort (Cohort A): Ponsegromab low dose; Main cohort (Cohort A): Ponsegromab medium dose and 6 more · For: Heart Failure
Sites: Fairhope, Alabama; Los Angeles, California; Washington D.C., District of Columbia · 122 sites in all
- Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05546476 · 187 participants · Start Nov 21, 2022 · Primary completion Mar 13, 2024
Drug: ponsegromab; Placebo for ponsegromab · For: Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer and 3 more
Sites: Conway, Arkansas; Little Rock, Arkansas; North Little Rock, Arkansas · 78 sites in all
- A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight LossNot yet recruiting
PfizerPfizer (PFE)
NCT07663630 · 80 participants (planned) · Start Oct 23, 2026 · Primary completion May 6, 2028
Drug: ponsegromab; placebo · For: Non-small Cell Lung Cancer (NSCLC); Cachexia
Sites: Decatur, Illinois; O'Fallon, Illinois; Garland, Texas · 7 sites in all
PfizerPfizer (PFE)
NCT05685264 · 18 participants · Start Jan 18, 2023 · Primary completion Jul 7, 2023
Drug: Ponsegromab; Ponsegromab · For: Healthy
Sites: Shanghai, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- FOXA2-mediated GDF15 secretion drives metastasis and CD8+ T cell exhaustion in clear cell renal cell carcinoma.
Huang C, Rui R, Guo H, et al. · J Clin Invest 2026
- STING-GDF15-STAT3 signaling contributes to neuroinflammation after intracerebral hemorrhage.
Zhu J, He L, Cao Y, et al. · Exp Neurol 2026
- GDF15 modulates aging-associated adaptions in the mechanoresponse of periodontal ligament fibroblasts.
Symmank J, Rieger E, Hennig CL, et al. · J Orofac Orthop 2026
- Novel Antibodies for Managing Cachexia.
Oswalt C, Crawford J · Annu Rev Med 2026
- Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.
Breen DM, Joaquim S, Paulhus BL, et al. · J Cachexia Sarcopenia Muscle 2026
- De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.
Ahn J, Cho R, Kim S, et al. · Exp Mol Med 2026
Also in development for Cachexia
- RilogrotugPhase 31 trial
AVEO Pharmaceuticals, Inc. · Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome
- DS010Phase 22 trials
Dartsbio Pharmaceuticals Ltd. · Cancer, Cachexia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.